Business Description
ISIN : US68404L2016
Share Class Description:
OPCH: Registered SharesTotal Employee Number:
8,266Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.16 | |||||
Equity-to-Asset | 0.37 | |||||
Debt-to-Equity | 0.94 | |||||
Debt-to-EBITDA | 2.88 | |||||
Interest Coverage | 6.31 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.57 | |||||
Beneish M-Score | -2.61 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.9 | |||||
3-Year EBITDA Growth Rate | 11.9 | |||||
3-Year EPS without NRI Growth Rate | 27.5 | |||||
3-Year FCF Growth Rate | 1.4 | |||||
3-Year Book Growth Rate | 3.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 10.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 5.62 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 60.11 | |||||
9-Day RSI | 58.69 | |||||
14-Day RSI | 58.24 | |||||
3-1 Month Momentum % | 4.17 | |||||
6-1 Month Momentum % | -30.75 | |||||
12-1 Month Momentum % | -21.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.47 | |||||
Quick Ratio | 0.98 | |||||
Cash Ratio | 0.24 | |||||
Days Inventory | 33.36 | |||||
Days Sales Outstanding | 31.51 | |||||
Days Payable | 48.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 4.8 | |||||
Shareholder Yield % | 8.99 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 19.06 | |||||
Operating Margin % | 6 | |||||
Net Margin % | 3.68 | |||||
EBITDA Margin % | 7.22 | |||||
FCF Margin % | 5.34 | |||||
OCF Margin % | 6.09 | |||||
ROE % | 15.74 | |||||
ROA % | 6.14 | |||||
ROIC % | 9.91 | |||||
3-Year ROIIC % | 51.81 | |||||
ROC (Joel Greenblatt) % | 79.03 | |||||
ROCE % | 12.96 | |||||
Years of Profitability over Past 10-Year | 5 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 17.98 | |||||
Forward PE Ratio | 12.72 | |||||
PE Ratio without NRI | 13.59 | |||||
Price-to-Owner-Earnings | 14.76 | |||||
PEG Ratio | 0.67 | |||||
PS Ratio | 0.67 | |||||
PB Ratio | 2.84 | |||||
Price-to-Free-Cash-Flow | 12.4 | |||||
Price-to-Operating-Cash-Flow | 10.87 | |||||
EV-to-EBIT | 13.71 | |||||
EV-to-Forward-EBIT | 12.86 | |||||
EV-to-EBITDA | 11.33 | |||||
EV-to-Forward-EBITDA | 11.11 | |||||
EV-to-Revenue | 0.82 | |||||
EV-to-Forward-Revenue | 0.81 | |||||
EV-to-FCF | 15.32 | |||||
Price-to-GF-Value | 0.6 | |||||
Price-to-Projected-FCF | 0.81 | |||||
Price-to-Median-PS-Value | 0.73 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.89 | |||||
Earnings Yield (Greenblatt) % | 7.29 | |||||
FCF Yield % | 8.48 | |||||
Forward Rate of Return (Yacktman) % | 21.66 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OPCH
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Option Care Health Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 5,693.516 | ||
| EPS (TTM) ($) | 1.33 | ||
| Beta | 0.331 | ||
| 3-Year Sharpe Ratio | -0.25 | ||
| 3-Year Sortino Ratio | -0.34 | ||
| Volatility % | 40.15 | ||
| 14-Day RSI | 58.24 | ||
| 14-Day ATR ($) | 0.645802 | ||
| 20-Day SMA ($) | 23.7745 | ||
| 12-1 Month Momentum % | -21.81 | ||
| 52-Week Range ($) | 18.01 - 36.8 | ||
| Shares Outstanding (Mil) | 149.79 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Option Care Health Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Option Care Health Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-24 08:30 | In 178 days | ||
| Annual report for 2026 | 2027-02-24 | In 177 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 | In 177 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-30 08:30 | In 61 days | ||
| Third quarter earnings results for 2026 | 2026-10-30 | In 60 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-29 08:30 | 22.48 (+1.35%) | ||
| Second quarter earnings results for 2026 | 2026-07-29 | 22.48 (+1.35%) | ||
| General meeting for 2026 | 2026-05-20 14:00 | 20.86 (+6.32%) | ||
| Bank of America Health Care Conference | 2026-05-12 10:40 | 19.83 (-3.97%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 08:30 | 26.87 (-0.37%) |
Option Care Health Inc Frequently Asked Questions
Guru Commentaries on NAS:OPCH
Option Care's performance was driven by better-than-expected guidance for 2025. OPCH’s value proposition of home-based infusion treatment remains unique in the care continuum. This positions the company well to capitalize on the growing demand for home-based healthcare solutions, which is increasingly favored by patients and providers alike.
Option Care's performance was driven by better-than-expected guidance for 2025. OPCH’s value proposition of home-based infusion treatment remains unique in the care continuum. This positions the company well to capitalize on the growing demand for home-based healthcare solutions, which is increasingly favored by patients and providers alike.
Option Care’s performance was driven by better-than-expected guidance for 2025. OPCH’s value proposition of home-based infusion treatment remains unique in the care continuum.
